Lessons in practicing cancer genomics and precision medicine

被引:0
|
作者
Patel, Jai N. [1 ]
机构
[1] Atrium Hlth, Levine Canc Inst, Dept Canc Pharmacol, Charlotte, NC USA
关键词
Cancer; genomics; precision; medicine; biomarker; clinical trials;
D O I
10.1080/23808993.2018.1526081
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Cancer genomic medicine has resulted in a shift from categorizing tumors solely based on their tissue of origin and histology to consideration of their molecular profile. Due to the large heterogeneity in clinical response, debilitating toxicities, and high treatment costs, it is imperative clinicians apply novel methods in precision medicine and cancer genomics to improve the benefit-risk profile. Areas covered: Cancer genomic medicine provides a personalized and practical method to enrich clinical efficacy, decrease toxicity, and enhance patient quality of life, thereby improving the return on investment for patient. The assimilation of cancer genomic medicine into clinical practice is rapidly advancing. This review addresses several lessons to consider as oncology researchers and clinicians begin to practice precision medicine and cancer genomics, including implications of patient sampling and clinical trials, molecular profiling and therapeutic interventions, and assimilation of cancer genomic medicine into the health system. Expert commentary: It is important that clinicians and researchers stay abreast of genomic advancements and understand how to effectively incorporate genomics into the cancer care continuum. A concerted and strategic effort must be made by researchers, clinicians, and cancer centers to adopt cancer genomic medicine as part of the new standard of care.
引用
收藏
页码:287 / 298
页数:12
相关论文
共 50 条
  • [21] Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine
    Conway, Jake R.
    Kofman, Eric
    Mo, Shirley S.
    Elmarakeby, Haitham
    Van Allen, Eliezer
    [J]. GENOME MEDICINE, 2018, 10
  • [22] Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy
    Kenneth M. Felsenstein
    Dan Theodorescu
    [J]. Nature Reviews Urology, 2018, 15 : 92 - 111
  • [23] Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine
    Jake R. Conway
    Eric Kofman
    Shirley S. Mo
    Haitham Elmarakeby
    Eliezer Van Allen
    [J]. Genome Medicine, 10
  • [24] Functional precision cancer medicine-moving beyond pure genomics
    Letai, Anthony
    [J]. NATURE MEDICINE, 2017, 23 (09) : 1028 - 1035
  • [25] Black Is Diverse: The Untapped Beauty and Benefit of Cancer Genomics and Precision Medicine
    George, Sophia
    Ragin, Camille
    Ashing, Kimlin Tam
    [J]. JCO ONCOLOGY PRACTICE, 2021, 17 (05) : 279 - +
  • [26] Cancer communication research in the era of genomics and precision medicine: a scoping review
    Kaphingst, Kimberly A.
    Peterson, Emily
    Zhao, Jingsong
    Gaysynsky, Anna
    Elrick, Ashley
    Hong, Soo Jung
    Krakow, Melinda
    Pokharel, Manusheela
    Ratcliff, Chelsea L.
    Klein, William M. P.
    Khoury, Muin J.
    Chou, Wen-Ying Sylvia
    [J]. GENETICS IN MEDICINE, 2019, 21 (08) : 1691 - 1698
  • [27] Uncertainty in Genomics Impacts Precision Medicine
    Pyeritz, Reed E.
    [J]. TRENDS IN GENETICS, 2021, 37 (08) : 711 - 716
  • [28] Cardiovascular Precision Medicine in the Genomics Era
    Dainis, Alexandra M.
    Ashley, Euan A.
    [J]. JACC-BASIC TO TRANSLATIONAL SCIENCE, 2018, 3 (02): : 313 - 326
  • [29] Precision medicine, genomics and drug discovery
    Cardon, Lon R.
    Harris, Tim
    [J]. HUMAN MOLECULAR GENETICS, 2016, 25 (R2) : R166 - R172
  • [30] Building the foundation for genomics in precision medicine
    Aronson, Samuel J.
    Rehm, Heidi L.
    [J]. NATURE, 2015, 526 (7573) : 336 - 342